Arthur Klausner

Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ.

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina.

X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents

Gentis, Inc. engages in the development and testing technologies for the minimally invasive treatments. The company was founded by Charles Cohen and Paul Ducheyne in 2000 and is headquartered in Wayne, PA.

Gem Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company that develops anthracycline derivatives used to eliminate cardiotoxicity side effect in chemotherapeutics. The company is headquartered in Birmingham, AL.

Part of Kiora Pharmaceuticals, Inc., Jade Therapeutics, Inc. develops pharmaceutical products. The company is based in Salt Lake City, UT. The company was founded by Barbara Wirostko. Jade Therapeutics was acquired by Kiora Pharmaceuticals, Inc. on March 07, 2016 for $5.10 million.